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INTRODUCTION
Epidemiological studies have shown that asthma causes a huge burden on health care. Although conventional therapy can control the symptoms of the majority of asthmatic patients, it may not be sufficient in some cases. Therefore, a new class of therapeutics for asthma is desirable. Asthma is an inflammatory airway disease involving a variety of cells, among which lymphocytes play a critical role. The activation of the transcription factor signal transducer and activator of transcription 5b (STAT5b) is known to play a important role in lymphocyte proliferation and apoptosis; in fact, the gene STAT5b is one of the targets in gene therapy for asthma (Zhu et al., 2003; Zhu, 2010) .
The potent ability of small interfering RNA (siRNA) to inhibit the expression of complementary RNA transcripts is being exploited as a new approach for treating diseases, including asthma (Maes et al., 2011) . siRNA is a short, double-stranded RNA (dsRNA) molecule that can target a specific sequence of mRNA for degradation via a cellular process known as RNA interference (RNAi) (Dorsett and Tuschl, 2004) . In this process, siRNA is incorporated into an RNA-induced silencing complex (RISC) that recognizes and cleaves the target sequence (Elbashir et al., 2001) . In particular, a targeted approach for intracellular delivery of siRNA to specific cell populations or tissues is highly desirable for the safety and efficacy of RNAibased therapeutics (Castanotto and Rossi, 2009) . Moreover, the advent of nanotechnology has greatly accelerated the development of drug delivery, and the field of RNA-based nanotechnology is now emerging (Guo, 2010) .
The packaging RNA (pRNA), one of the 6 copies of the RNA components within the nanomotor of the bacteriophage phi29, is 117 nucleotide (nt) long and has been developed and manipulated to produce chimeric RNAs that form dimers by interlocking of the right-and lefthand loops (Shu et al., 2003; Lee et al., 2009) . pRNA monomers can fold into a stable and unique secondary structure that serves as the building block to form nanostructures by bottom-up assembly. The pRNA molecule contains 2 independent folding domains with distinct functions: 5ꞌ-/3ꞌ-double-stranded helical domain and intermolecular interaction domain (loop-loop region). Replacement or insertion of oligonucleotides preceding nt #23 or following nt #97 does not interfere with the formation of dimmers as long as the strands are paired (Shu et al., 2009 ). Therefore, the 5ꞌ/3ꞌ-proximate double-stranded helical region of the pRNA can be redesigned to carry additional sequences without altering its secondary structure or intermolecular interactions. On the basis of these characteristics, incubation of cells with pRNA dimmers, one subunit of which carried siRNA and the other, a receptor-binding moiety, resulted in successful binding, entry, and silencing of target genes (Guo et al., 2005; Zhang et al., 2009; Zhou et al., 2011) .
In this study, we constructed pRNA-siRNA/STAT5b monomers and pRNA-aptamer/ CD4 monomers and then formed heterodimers. One subunit of the dimer contained an aptamer molecule at its 5ꞌ-end, which was used to target cell recognition, and the other harbored a moiety of therapeutic siRNA for gene therapy. Since CD4+ T lymphocytes are the most important cells in the development of asthma and they are present at a high percentage in asthmatic spleen lymphocytes, we chose aptamer/CD4 as a ligand to interact with the CD4 molecule in CD4+ T lymphocytes. Without any other transfection, the pRNA dimer strongly inhibited the mRNA expression of STAT5b, while none of the pRNA monomers had any effect. Further, we found that pRNAs had little cytotoxicity. These data indicate that pRNA is a promising candidate for targeted gene therapy in asthma.
MATERIAL AND METHODS
Preparation of pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 and pRNA heterodimer formation pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 were synthesized by in vitro transcription of cDNA fragments encoding the chimeric pRNA-siRNA/STAT5b or pRNAaptamer/CD4. The cDNA fragments were produced by polymerase chain reaction (PCR) according to standard procedures. The template sequences and primer sequences for PCR were specifically designed according to the previous reports (Zhang et al., 2009 ) and synthesized (Sangon, China). All the template and primer sequences used are listed ( Figure 1 ). Extensive studies of pRNA have revealed that 2 pRNA monomers form a dimer through the interaction of the complementary left-and right-hand loops. In this study, we previously designed pRNA-siRNA/STAT5b (A-bꞌ), which contains a right-hand loop A (5ꞌ-G 38 G 39 A 40 C 41 ) and a left-hand loop bꞌ (3ꞌ-U 74 G 75 C 76 G 77 ); these can together pair with the left-hand loop aꞌ (3ꞌ-C 121 C 120 U 119 G 118 ) and the right-hand loop B (5ꞌ-A 81 C 82 G 83 C 84 ) of pRNA-aptamer/CD4 (B-aꞌ), respectively.
The 5ꞌ-end primer contained the T7 phage 2.5 promoter sequence followed by a sense sequence of siRNA/STAT5b and the 3ꞌ-end primer contained the antisense sequence of siRNA/ STAT5b. With this, the sequence of siRNA/STAT5b was added to the 5ꞌ/3ꞌ double-stranded helical region of the pRNA after PCR, thereby resulting in the formation of pRNA-siRNA/ STAT5b. Similarly, in order to construct pRNA-aptamer/CD4, the 5ꞌ-end primer contained the T7 phage 2.5 promoter sequence followed by the aptamer/CD4 sequence. The siRNA/STAT5b sequence was designed (Ambion, USA). A previous report has indicated that 10 copies of aptamer/CD4 interact with CD4 molecule specifically and that each of them can inhibit CD4+ lymphocyte proliferation differently (Kraus et al., 1998) . In this study, we chose the copy of aptamer/CD4, which has the minimum inhibiting capacity.
pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 were designed previously, and their structure were evaluated through a software application (http://novacripta.cbm.uam.es/bioweb/ courses/UFV0708/tema08/index.html) in order to ensure the correct secondary structure (Figure 2A and B) . Then, the secondary structure of the pRNA dimer was predicted ( Figure 2C ). To synthesize pRNA-siRNA/STAT5b and pRNA-aptamer/CD4, in vitro transcription was conducted using Riboprobe System-T7 (Promega, USA) according to manufacturer instructions. Briefly, the PCR-amplified cDNA fragments containing the T7 phage 2.5 promoter were transcribed with T7 RNA polymerase in the presence of rATP, rCTP, rGTP, and rUTP. Transcription products were digested by DNase and were then precipitated with ethanol and resuspended in sterilized DEPC-treated water. The concentration of the pRNA chimera products was measured using a spectrophotometer. Then, the products were confirmed by 8% native polyacrylamide gel electrophoresis (PAGE) using TBM running buffer (89 mM Tris-base, 200 mM boric acid, and 5 mM MgCl 2 , pH 7.6) (Chen et al., 2000) , in which the polyacrylamide gel was poured without sodium dodecyl sulfate.
It has been proven that in a solution containing 5 mM magnesium, 2 pRNA monomers with base-pairing loop (for example, A-bꞌ pRNA and B-aꞌ pRNA) can easily form a dimer through the interaction of the complementary left-and right-hand loops (Shu et al., 2004) . In this study, the pRNA heterodimer was prepared by mixing pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 in 1:1 molar ratio in a solution containing 5 mM Mg 2+ and RNAseOUT RNAse inhibitor.
Murine asthma model and spleen lymphocytes cultivation
Twenty female BALB/c mice (6-8 weeks old, Experimental Animal Center of Guangdong Province, China) were randomly divided into 2 groups: the asthma group and the control group. Mice were sensitized to become asthmatic as described previously (North et al., 2009) .
After completing the asthma model protocol, bronchial lung sections were obtained and stained by hematoxylin and eosin to evaluate the model. At the same time, the spleen lymphocytes were obtained using the mouse lymphocyte separation medium (Dakewe Biotech Company, China) according to manufacturer instructions.
The lymphocytes were cultured in six-well plates (1 x 10 6 cells per well) with RPMI1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum and penicillin/ streptomycin (Invitrogen, USA). IL-2 (0.02 µg) cytokines (PeproTech, USA) were added to every well, and the lymphocytes were cultured in a 5% CO 2 incubator.
Specific gene silencing by pRNA chimera and dimer
After culturing for 24 h, the lymphocytes were directly incubated with 3 µg pRNAsiRNA/STAT5b, 3 µg pRNA-aptamer/CD4, or 6 µg pRNA dimer without any other transfection for 48 h. In addition, a control group was recruited.
Reverse transcription (RT)-PCR
Total RNA was extracted from cells at the post-incubation indicated time points using Trizol reagent (Invitrogen). RT was conducted according to manufacturer instructions using Quant Reverse Transcriptase (Tiangen Biotech Company, China) and followed by PCR under the standard conditions to amplify STAT5b and cDNA of GAPDH. The primer sequences of the gene STAT5b are as follows: forward 5ꞌ-CAACCGGGAGAATTTGCCAG-3ꞌ, reverse 5ꞌ-CCATCATTCCAGTGAGGCTTGA-3ꞌ, and the product was 102 nt. The primer sequences of the gene GAPDH are as follows: forward 5ꞌ-AACTTTGGCATTGTGGAAGG-3ꞌ, reverse 5ꞌ-GGATGCAGGGATGATGTTCT-3ꞌ, and the product was 132 nt. The PCR product from each sample was analyzed by 1.5% agarose gel electrophoresis.
Cytotoxicity test by CCk-8 kit
Safety is very important to a drug. Therefore, we used the CCK-8 kit (Dojindo, Japan) to evaluate the cytotoxicity of the pRNA chimera. In brief, the lymphocytes were incubated with the CCK-8 kit for 4 h after incubation with pRNA chimera for the indicated time. The readings were then obtained using a spectrophotometer.
RESULTS

Photomicrographs of lung sections
Asthma is an inflammatory airways disease. Photomicrographs of lung sections obtained from the asthma group showed that there was an apparent increase in the thickness of the airway epithelium and obvious submucosal cell infiltration (Figure 3) . On the other hand, no signs of inflammation were evident in the lung sections of the control group. These data proved that asthma group mice had serious airway inflammation. Thus, a murine asthma model was successfully established. Additionally, although not an objective evidence, asthma symptoms such as shortness of breath were also present in the mice of the asthma group mice, but absent in the control group mice during the asthma modeling process. 
Synthesis of pRNA chimera
The cDNA fragment of pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 was constructed by PCR. After that, the PCR products were confirmed and purified by agarose electrophoresis ( Figure 4A and B). In vitro transcription was then conducted, and transcription products were confirmed by native PAGE ( Figure 4C) . We found that all the bands were at the expected positions relative to the mark. Thus, pRNA chimera is easy to design and assemble bottom-up. 
Inhibition ability of pRNA chimera and dimer
We observed that STAT5b expression levels in the pRNA dimer group were less than those in other groups, while those in the pRNA-siRNA/STAT5b group and pRNA-siRNA/ CD4 group were similar to that in the control group ( Figure 5) . Therefore, the data indicate that when incubated with lymphocytes directly, pRNA dimers carrying both siRNA and aptamer play an inhibitory role, while pRNA chimera does not. RT-PCR to evaluate the inhibition ability of pRNA chimera and dimer. Lanes 1 and 5 = Control groups; lanes 2 and 6 = pRNA-siRNA/STAT5b groups; lanes 3 and 7 = pRNA-aptamer/CD4 groups; lanes 4 and 8 = pRNA dimer groups. STAT5b gene expression of the pRNA dimer group is less than other groups.
Cytotoxicity of pRNA chimera
We found no significant difference between the control group, pRNA-siRNA/STAT5b group, and pRNA-aptamer/CD4 group (Figure 6 ). These data proved that pRNA chimera had minimal cytotoxicity. 
DISCUSSION
During the last decade, RNA interference has shown great potential as a therapeutic modality for various diseases, including asthma. However, in drug development, one of the most critical barriers for clinical application is the non-specific distribution of the drug in the body after administration. This non-specific delivery not only reduces the therapeutic efficiency and gives rise to harmful adverse effects but also causes drug wastage, resulting in increased cost. With this in view, the development of an effective system for targeted delivery of therapeutic molecules is the main goal of the present study.
pRNA has been reported to have application in nanotechnology and nanomedicine. Through the interaction of 2 reengineered interlocking loops, pRNAs can form nanoscale dimers, even trimers and hexamers. This unique ability of pRNA makes it a versatile polyvalent vehicle to combine with therapeutic siRNAs for treating and other ligand for cell recognition and maybe applied as a therapeutic nanoplatform, which can improve the targeting, solubility, and pharmacokinetic/distribution properties of drugs (Lee et al., 2009 ).
Many genes have been reported to be definitively related to asthma. We chose siRNA targeting the STAT5b gene, a critical gene involved in lymphocyte proliferation and apoptosis, as an effective therapeutic agent to test the novel delivery system.
The pRNA molecule can be employed as a novel RNA vector to carry siRNA or an aptamer molecule. Previous reports indicate that the pRNA-siRNA chimera exerts the silencing function of siRNA effectively and that the silencing efficiency of this chimera is similar to or even better than that of free siRNA (Zhang et al., 2009; Tarapore et al., 2011) . Similarly, the pRNA-aptamer chimera interacts with the specific receptor, as expected (Guo et al., 2005 ; Figure 6 . CCK-8 to evaluate cytotoxicity of pRNA chimera. There is no significant difference between the three groups. The values shown are reported as means ± SD of the data from three separated experiments. Zhou et al., 2011) . In this study, we built pRNA chimera using a synthetic PCR template, but not plasmid containing pRNA sequences, and proved that the pRNA chimeras were successfully built. Next, we found that without any other transfection, pRNA dimer carrying both siRNA/STAT5b and aptamer/CD4 strongly inhibited mRNA expression of STAT5b. On the other hand, incubation of pRNA-siRNA/STAT5b or pRNA-aptamer/CD4 with lymphocytes did not have any effect on the expression of STAT5b. The data indicate that pRNA dimer can deliver siRNA to cells and work as expected, maybe the mechanism is via aptamer as a ligand to interact with specific receptor. Further experiments are needed to confirm the ability of pRNA-aptamer/CD4 to specifically interact with the CD4 molecule.
Biosafety is the most important feature of a drug. If a drug is highly cytotoxic, it cannot have widespread clinical application even if it is highly efficient. We showed that both pRNA-siRNA/STAT5b and pRNA-aptamer/CD4 have minimal cytotoxicity. Therefore, pRNA warrants further investigation as a novel nanovehicle.
